Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could help babies fight RSV faster

NCT ID NCT07482657

Disease control Sponsor: Enanta Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 4 times

Summary

This study tests an experimental oral drug called zelicapavir in 150 children aged 1 month to 3 years who have respiratory syncytial virus (RSV). The drug aims to stop the virus from multiplying and speed up recovery. Half the children will get the drug, half a placebo, and researchers will track how quickly symptoms like cough and fever go away.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zelicapavir (oral suspension)
What this could lead to
If successful, this could provide a new oral treatment option for young children with RSV, potentially reducing hospital stays and symptom duration.
What could go wrong
This is an early Phase 2 trial with only 150 participants, so results may not confirm effectiveness. The drug may cause side effects or fail to improve recovery compared to placebo.
Why investors are watching

Enanta Pharmaceuticals is testing zelicapavir, an oral drug for respiratory syncytial virus (RSV), in a Phase 2 trial with 150 children aged 28 days to 36 months. For a small-cap company, this readout tests whether its drug can treat RSV in young children, a group with high hospitalization risk. A clear result matters because Enanta's value depends on this drug's success.

If it works: If the trial shows zelicapavir is safe and effective, Enanta could have a treatment for RSV in infants and toddlers, a large unmet need. That result could support moving the drug into later-stage trials and attract partnership interest.

If it fails: Phase 2 trials often fail to show benefit, and this one could miss its goals or reveal safety problems. A negative or unclear result would set the program back and likely reduce the company's prospects, since Enanta has few other late-stage assets.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

28 days to 36 months

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants diagnosed with RSV infection using an approved diagnostic assay, without known and/or documented coinfection with SARS-CoV-2 or influenza * Participant has signs of RSV infection with onset ≤3 days (72 hours) at the time of randomization * In the Investigator's opinion, the participant's caregiver understands and is able to comply with protocol requirements, instructions, and restrictions, and the participant is likely to complete the study as planned. The caregiver(s) should be of legal age. Exclusion Criteria: * Participant has any condition that in the opinion of the Investigator would interfere with the evaluation of the study drug or participant safety. * Participant has underlying immune deficiency. Participants with immunoglobulin A deficiency are not excluded. * Participant has had major surgery within 6 weeks prior to randomization or has major surgery planned during the course of the study. * Participant is currently taking either chronically or has taken within 7 days prior to randomization, or is anticipated to receive during the course of the study, systemic medications that are known to cause immunosuppression other than corticosteroids for \>5 days. * Participant has received an investigational agent within the last 30 days or 5 half-lives of the investigational agent, whichever is longer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Respiratory syncytial virus (RSV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Respiratory syncytial virus (RSV) RSV RSV infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center of Excellence for Pediatric Infectious Diseases and Vaccines Faculty of Medicine, Chulalongkorn University (CE-PID)

    RECRUITING

    Bangkok, 10330, Thailand

  • Chiangrai Prachanukroh Hospital

    RECRUITING

    Chiang Rai, 57000, Thailand

  • Khon Kaen Hospital

    RECRUITING

    Khon Kaen, 40000, Thailand

  • Lampang Hospital

    RECRUITING

    Lampang, 52000, Thailand

  • Lamphun Hospital

    RECRUITING

    Lamphun, 51000, Thailand

  • Maha Sarakham Hospital

    RECRUITING

    Maha Sarakham, 44000, Thailand

  • Maharaj Nakorn Chiang Mai Hospital

    RECRUITING

    Chiang Mai, 50200, Thailand

  • Nakornping Hospital

    RECRUITING

    Chiang Mai, 50180, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.